Correlation of FFR and iFR With Cardiac PET Perfusion (at Rest and Under Adenosine) in the Evaluation of Intermediate Coronary Stenoses in Patients With Severe Aortic Valve Stenosis

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Aortic valve stenosis (AS) affects 2-7% of persons \> 65 years, symptoms include: angina and dyspnea, dizziness and syncope. Coincidence of coronary artery disease (CAD), also presenting with angina and dyspnea, in patients with AS between 40 - 65% . Angina in AS caused by significant reduction of coronary flow reserve (CFR). CFR is the ratio of maximal flow increase in the coronary vessel bed during maximal hyperaemia (medically or exercise induced). FFR (fractional flow reserve) use in patients with AS potentially invalid due to dysfunctional CFR leading to potential undertreatment of CAD in these patients.CFR disturbance in AS mainly due to myocardial overload causing concentric hypertrophy, increased oxygen consumption and neurohormonal activation leading to increased vascular resistance. Current studies are investigating the validity of FFR and iFR in AS patients. Recent data demonstrate very good correlation between FFR and iFR derived values to PET myocardial perfusion imaging values in patients with no evidence of AS. Our study aims to investigate the diagnostic performance of FFR and iFR in intermediate-grade coronary stenosis in patients with severe aortic valve disease and correlate FFR- and iFR derived values with those extracted from PET-perfusion Imaging.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 65
Healthy Volunteers: f
View:

• patients with severe aortic Stenosis eligible for transcatheter aortic stenosis

• left ventricular ejection fraction \> 55%

• no intolerance of Adenosin

• no history of bradycardia, atrioventricular Blockade

• intermediate coronary Stenosis with FFR\> 0.8

• Age \>65

Locations
Other Locations
Germany
Herz- und Diabeteszentrum, NRW
RECRUITING
Bad Oeynhausen
Contact Information
Primary
Tanja Rudolph, MD
trudolph@hdz-nrw.de
+495731971258
Backup
Astrid Kleemeyer
akleemeyer@hdz-nrw.de
+49495731971258
Time Frame
Start Date: 2021-06-01
Estimated Completion Date: 2025-09-30
Participants
Target number of participants: 20
Sponsors
Leads: Heart and Diabetes Center North-Rhine Westfalia

This content was sourced from clinicaltrials.gov